Neovascular Glaucoma Clinical Trial
Official title:
An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma
Proliferative ischemic retinopathies lead to a formation of abnormal vessels on the iris
surface induced by an increased level of vascular endothelial growth factor (VEGF). In
progressive stages fibrovascular membranes occlude the anterior chamber angle which inhibits
aqueous outflow resulting in neovascular glaucoma. The increased intraocular pressure is
often difficult to control and frequently results in loss of vision.
The aim of this study is to analyze the short- and long-term outcome after adjuvant
intraocular Ranibizumab application in patients with neovascular glaucoma and rubeosis and
to analyze the role of ranibizumab within a holistic treatment regime.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00491712 -
Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection
|
N/A | |
Recruiting |
NCT04519619 -
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
|
||
Completed |
NCT04970251 -
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
|
N/A | |
Completed |
NCT02805257 -
Ahmed Glaucoma Valve Surgery With Mitomycin-C
|
Phase 2 | |
Recruiting |
NCT02067013 -
Analysis of Aqueous and Vitreous Humor
|
Phase 2 | |
Completed |
NCT00524758 -
Oculusgen (Ologen) Glaucoma MMC Control in Estonia
|
Phase 3 | |
Withdrawn |
NCT00727038 -
Lucentis for New Onset Neovascular Glaucoma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02947867 -
Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
|
Phase 2/Phase 3 | |
Completed |
NCT01711879 -
Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
|
N/A | |
Terminated |
NCT02260219 -
Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma
|
N/A | |
Withdrawn |
NCT00441181 -
Effects of Travoprost on Neovascular Glaucoma
|
N/A | |
Completed |
NCT01051583 -
Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma
|
Phase 2 | |
Completed |
NCT05156021 -
A Study on the Treatment Strategy of NVG Secondary to PDR
|
N/A | |
Terminated |
NCT01301378 -
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
|
N/A | |
Not yet recruiting |
NCT05316142 -
Any Unique Identifier Assigned to the Protocol by the Sponsor
|
N/A | |
Recruiting |
NCT04844619 -
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
|
Phase 1 | |
Completed |
NCT03154892 -
The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
|
N/A |